# ACADIA Pharmaceuticals Inc. (ACAD) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.57, market value $3.5 billion.

## Valuation
- **P/E (trailing): 9.2×** (5-yr avg 12.6×, 3-yr avg 12.6×). ACADIA Pharmaceuticals Inc. trades at 9.2× trailing earnings, well below its own five-year average of 12.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.3×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.32**. A PEG of 0.32 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.1×**. Each dollar of revenue is priced at 3.1×.
- **Price / book: 2.7×**. The shares trade at 2.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 4.1%** (5-yr avg -0.0%). Free cash flow equals 4.1% of the market value, above its five-year average of -0.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 10.8%**. The inverse of the P/E: 10.8% of the price is earned each year.

## Profitability
- **Operating margin: 7.6%**. 7.6% of revenue is left after running the business.
- **Net margin: 36.5%**. 36.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 31.9%**. 31.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 24.3%**. Each dollar of assets produces 24.3% of profit.

## Growth
- **Revenue growth (1 yr): 11.9%** (3-yr 27.5%/yr, 5-yr 19.4%/yr). Revenue grew 11.9% over the last year, against 19.4% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 69.1%**. Earnings per share rose 69.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 3.83** (quick 3.83). Current assets cover the next year's liabilities 3.83 times.
- **Altman Z-score: 8.92**. A Z-score of 8.92 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. ACADIA Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (19 analysts). 19 analysts cover ACADIA Pharmaceuticals Inc.; the consensus is buy, with an average price target of $30.53 (+48% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -8.0%** (YTD -23.0%, 3-mo -24.2%). The shares are down 8.0% over twelve months including dividends.
- **From 52-week high: -33.6%** (11.9% above the low). Trading 34% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 0.77** (volatility 39%). Beta of 0.77 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ACAD · Page: https://foliofundamentals.com/stocks/acad

Not investment advice.